A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology

The progress in Alzheimer’s disease (AD) treatment suggests a combined therapeutic approach targeting the two lesional processes of AD, which include amyloid plaques made of toxic Aβ species and neurofibrillary tangles formed of aggregates of abnormally modified Tau proteins. A pharmacophoric design, novel drug synthesis, and structure-activity relationship enabled the selection of a polyamino biaryl PEL24-199 compound. The pharmacologic activity consists of a non-competitive β-secretase (BACE1) modulatory activity in cells. Curative treatment of the Thy-Tau22 model of Tau pathology restores short-term spatial memory, decreases neurofibrillary degeneration, and alleviates astrogliosis and neuroinflammatory reactions. Modulatory effects of PEL24-199 towards APP catalytic byproducts are described in vitro, but whether PEL24-199 can alleviate the Aβ plaque load and associated inflammatory counterparts in vivo remains to be elucidated. We investigated short- and long-term spatial memory, Aβ plaque load, and inflammatory processes in APPSwe/PSEN1ΔE9 PEL24-199 treated transgenic model of amyloid pathology to achieve this objective. PEL24-199 curative treatment induced the recovery of spatial memory and decreased the amyloid plaque load in association with decreased astrogliosis and neuroinflammation. The present results underline the synthesis and selection of a promising polyaminobiaryl-based drug that modulates both Tau and, in this case, APP pathology in vivo via a neuroinflammatory-dependent process.

[1]  D. Holtzman,et al.  TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways , 2022, Cell.

[2]  L. Buée,et al.  Pathological changes induced by Alzheimer’s brain inoculation in amyloid-beta plaque-bearing mice , 2022, bioRxiv.

[3]  P. Verwaerde,et al.  AZP2006, a new promising treatment for Alzheimer’s and related diseases , 2021, Scientific Reports.

[4]  L. Buée,et al.  A ß-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration , 2021, Frontiers in Pharmacology.

[5]  Kira E. Poskanzer,et al.  Reactive astrocyte nomenclature, definitions, and future directions , 2021, Nature Neuroscience.

[6]  K. Blennow,et al.  Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease , 2020, Translational Psychiatry.

[7]  B. de Strooper,et al.  The β-Secretase BACE1 in Alzheimer’s Disease , 2020, Biological Psychiatry.

[8]  J. Sontag,et al.  Disturbances in PP2A methylation and one-carbon metabolism compromise Fyn distribution, neuritogenesis, and APP regulation , 2020, The Journal of biological chemistry.

[9]  W. M. van der Flier,et al.  Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology , 2020, Alzheimer's Research & Therapy.

[10]  N. Fitz,et al.  Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice , 2020, Molecular Neurodegeneration.

[11]  J. Pejchal,et al.  Is It the Twilight of BACE1 Inhibitors? , 2020, Current neuropharmacology.

[12]  Peichang Wang,et al.  Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model , 2020, Alzheimer's Research & Therapy.

[13]  J. Westermarck,et al.  Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer’s Disease Pathogenesis in Cell and Animal Models , 2020, Neurotherapeutics.

[14]  T. Ben-Hur,et al.  Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer’s disease mice , 2020, Journal of Neuroinflammation.

[15]  Thamir Salman Bachari.  Membrane , 2020, Definitions.

[16]  L. Buée,et al.  New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease , 2019, Neurobiology of Disease.

[17]  Melanie A. Huntley,et al.  Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. , 2019, Cell reports.

[18]  Weihong Song,et al.  BACE2, a conditional β-secretase, contributes to Alzheimer's disease pathogenesis. , 2019, JCI insight.

[19]  L. Buée,et al.  A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors. , 2018, European journal of medicinal chemistry.

[20]  B. Fiebich,et al.  Role of Microglia TLRs in Neurodegeneration , 2018, Front. Cell. Neurosci..

[21]  B. Hyman,et al.  &bgr;-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals , 2018, Journal of neuropathology and experimental neurology.

[22]  L. Buée,et al.  New phenylaniline derivatives as modulators of amyloid protein precursor metabolism. , 2018, Bioorganic & medicinal chemistry.

[23]  R. Yan,et al.  BACE1 deletion in the adult mouse reverses preformed amyloid deposition and improves cognitive functions , 2018, The Journal of experimental medicine.

[24]  P. Gleeson,et al.  GGA1 regulates signal-dependent sorting of BACE1 to recycling endosomes, which moderates Aβ production , 2018, Molecular biology of the cell.

[25]  Juhyun Song,et al.  Perspectives in Lipocalin-2: Emerging Biomarker for Medical Diagnosis and Prognosis for Alzheimer's Disease , 2018, Clinical nutrition research.

[26]  Bin Zhang,et al.  Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation , 2017, Nature Medicine.

[27]  Ernesto Fedele,et al.  The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind , 2017, Current neuropharmacology.

[28]  Pedro Rosa-Neto,et al.  Synergistic interaction between amyloid and tau predicts the progression to dementia , 2017, Alzheimer's & Dementia.

[29]  Beth Stevens,et al.  Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice , 2017, Science Translational Medicine.

[30]  Manoj Kumar,et al.  INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.

[31]  M. Lynch,et al.  Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease , 2016, Brain, Behavior, and Immunity.

[32]  Ben A. Barres,et al.  Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.

[33]  E. Kandel,et al.  PP2A methylation controls sensitivity and resistance to β-amyloid–induced cognitive and electrophysiological impairments , 2016, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Tan,et al.  The Role of Cdk5 in Alzheimer’s Disease , 2016, Molecular Neurobiology.

[35]  Stephen F. Carter,et al.  Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography , 2015, Scientific Reports.

[36]  Jeremy A. Miller,et al.  Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: a co-expression meta-analysis , 2015, Acta Neuropathologica Communications.

[37]  Keith A. Vossel,et al.  Tau reduction prevents A-induced axonal transport deficits by blocking activation of GSK 3 , 2015 .

[38]  K. Blennow,et al.  APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons , 2015, Cell reports.

[39]  G. Baillie,et al.  The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease , 2015, Future science OA.

[40]  B. Hyman,et al.  Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease , 2015, Acta neuropathologica communications.

[41]  A. Delacourte,et al.  Chloroquine and chloroquinoline derivatives as models for the design of modulators of amyloid Peptide precursor metabolism. , 2015, ACS chemical neuroscience.

[42]  G. Taglialatela,et al.  NFκB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease , 2015, Neuron.

[43]  Patty C. Kandalepas,et al.  The normal and pathologic roles of the Alzheimer's β-secretase, BACE1. , 2014, Current Alzheimer research.

[44]  N. Andreasen,et al.  Pathways to Alzheimer's disease , 2014, Journal of internal medicine.

[45]  R. Vassar,et al.  Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.

[46]  X. Yao,et al.  Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  V. Laporte,et al.  Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. , 2012, The American journal of pathology.

[48]  E. Hol,et al.  GFAP Isoforms in Adult Mouse Brain with a Focus on Neurogenic Astrocytes and Reactive Astrogliosis in Mouse Models of Alzheimer Disease , 2012, PloS one.

[49]  A. Vortmeyer,et al.  Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons , 2012, Nature Neuroscience.

[50]  J. A. Boer,et al.  Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  W. Annaert,et al.  Membrane Trafficking Pathways in Alzheimer's Disease , 2012, Traffic.

[52]  B. Penke,et al.  TLR2 Is a Primary Receptor for Alzheimer’s Amyloid β Peptide To Trigger Neuroinflammatory Activation , 2012, The Journal of Immunology.

[53]  B. de Strooper,et al.  Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. , 2012, Cold Spring Harbor perspectives in medicine.

[54]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[55]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[56]  G. Zamponi.  Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .

[57]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[58]  C. Palencia,et al.  Fibrillar Amyloid-β Peptides Activate Microglia via TLR2: Implications for Alzheimer’s Disease1 , 2008, The Journal of Immunology.

[59]  A. Delacourte,et al.  Alkalizing Drugs Induce Accumulation of Amyloid Precursor Protein By-products in Luminal Vesicles of Multivesicular Bodies* , 2007, Journal of Biological Chemistry.

[60]  A. Delacourte,et al.  Intracellular pH regulates amyloid precursor protein intracellular domain accumulation , 2007, Neurobiology of Disease.

[61]  M. Famulok,et al.  GGA1 Is Expressed in the Human Brain and Affects the Generation of Amyloid β-Peptide , 2006, The Journal of Neuroscience.

[62]  Brian J. Bacskai,et al.  Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease , 2006, Neurobiology of Disease.

[63]  B. Hyman,et al.  GGA1 Acts as a Spatial Switch Altering Amyloid Precursor Protein Trafficking and Processing , 2006, The Journal of Neuroscience.

[64]  Y. Suh,et al.  Phosphorylation of Amyloid Precursor Protein (APP) at Thr668 Regulates the Nuclear Translocation of the APP Intracellular Domain and Induces Neurodegeneration , 2006, Molecular and Cellular Biology.

[65]  A. Delacourte,et al.  Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism , 2005, Neurobiology of Disease.

[66]  Fei Liu,et al.  Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation , 2005, The European journal of neuroscience.

[67]  Michael Famulok,et al.  GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network , 2005, Molecular and Cellular Neuroscience.

[68]  T. V. Van Dooren,et al.  β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Increases Amyloid Deposition in Brain Parenchyma but Reduces Cerebrovascular Amyloid Angiopathy in Aging BACE × APP[V717I] Double-Transgenic Mice , 2004 .

[69]  E. Godaux,et al.  A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.

[70]  H. Cai,et al.  Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients , 2004 .

[71]  M. D'Andrea,et al.  Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains , 2003, Brain Research.

[72]  P. Wong,et al.  Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.

[73]  A. Delacourte,et al.  Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease , 2002, Neurology.

[74]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[75]  Patrick L. McGeer,et al.  Inflammation, autotoxicity and Alzheimer disease , 2001, Neurobiology of Aging.

[76]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[77]  P. Paganetti,et al.  Effect of alkalizing agents on the processing of the β-amyloid precursor protein , 1996, Brain Research.

[78]  P. Paganetti,et al.  Effect of alkalizing agents on the processing of the beta-amyloid precursor protein. , 1996, Brain research.

[79]  P. Greengard,et al.  Chloroquine inhibits intracellular degradation but not secretion of Alzheimer beta/A4 amyloid precursor protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[80]  C. Barnes.  Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. , 1979, Journal of comparative and physiological psychology.